AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DOJ Subpoenas Major Law Firms in Trump Executive Order Dispute 
25 Democratic-Led States Sue Trump Administration Over New Global Tariffs 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
OpenAI Restricts Astra AI Over Cyberattack Risks 
US Supreme Court Lets $655.5 Million Judgment Against Palestinian Authorities Stand During Appeal 
Appeals Court Rejects Trump Bid to Reinstate $100,000 H-1B Visa Fee 
Eduardo Bolsonaro Granted U.S. Green Card Amid Brazil Legal Battle and Tariff Dispute 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
